Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 339 followers
Latest posts
Last updated 17 minutes ago
Implantica finally nabs FDA approval 8 years after EU green light for reflux implant
17 minutes ago
The FDA has signed off on Implantica’s gastroesophageal reflux disease (GERD) implant...
Vacant lab space, shrinking workforce put Mass. in ‘unique position’ for biotech bounceback
about 3 hours ago
A new report on the health of the Massachusetts biotech scene has...
Capricor secures reprieve as FDA extends DMD cell therapy review
about 4 hours ago
The FDA has extended its review of Capricor Therapeutics’ Duchenne muscular dystrophy...
Qiagen appoints new chief executive after 9-month search
about 21 hours ago
Molecular diagnostics specialist Qiagen has a new CEO as Jonathan M. Pratt...
Spruce’s successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug
about 22 hours ago
Spruce Biosciences has taken another step toward filing for FDA approval of...
TME holds onto $1B dream for brain cancer drug as search for partners nears conclusion
about 22 hours ago
TME Pharma’s hunt for a partner for its brain cancer drug is...
Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings
about 24 hours ago
The FDA has put a clinical hold on Regenxbio’s RGX-121 over asymptomatic...
Roche, Eli Lilly net FDA approval for first-of-its-kind Alzheimer’s biomarker blood test
about 24 hours ago
Roche and Eli Lilly have won FDA clearance for their latest Alzheimer’s...
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
1 day ago
Roche has taken its obesity strategy into uncharted territory via a $190...
Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug
4 days ago
Werewolf Therapeutics’ hunt for strategic alternatives has ended. Ambros Therapeutics has agreed...
Chutes & Ladders—Neumora shuffles leadership ahead of IND
4 days ago
Joshua Pinto, Ph.D., has been appointed chief executive officer of Neumora Therapeutics...
Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
4 days ago
As the dust settles on phase 3 data that added $45 billion...